Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | L485_P490delinsFS |
Impact List | indel |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF L485_P490delinsFS results in a deletion of six amino acids in the protein kinase domain of the Braf protein from amino acids 485 to 490, combined with the insertion of a phenylalanine (F) and a serine (S) at the same site (UniProt.org). L485_P490delinsY results in increased Mek/Erk phosphorylation, is transforming, and is associated with resistance to select RAF inhibitors in culture (PMID: 37656784). |
Associated Drug Resistance | Y |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF L485_P490delinsFS |
Transcript | NM_004333.6 |
gDNA | chr7:g.140778038_140778055delinsGCTAAA |
cDNA | c.1453_1470delinsTTTAGC |
Protein | p.L485_P490delinsFS |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001378468.1 | chr7:g.140778038_140778055delinsGCTAAA | c.1453_1470delinsTTTAGC | p.L485_P490delinsFS | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140778038_140778055delinsGCTAAA | c.1453_1470delinsTTTAGC | p.L485_P490delinsFS | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140778038_140778055delinsGCTAAA | c.1453_1470delinsTTTAGC | p.L485_P490delinsFS | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140778038_140778055delinsGCTAAA | c.1453_1470delinsTTTAGC | p.L485_P490delinsFS | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140778038_140778055delinsGCTAAA | c.1453_1470delinsTTTAGC | p.L485_P490delinsFS | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | Trametinib | Preclinical - Biochemical | Actionable | In a preclinical study, Mekinist (trametinib) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - resistant | Vemurafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Zelboraf (vemurafenib) did not inhibit Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - resistant | Encorafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Braftovi (encorafenib) did not inhibit Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | GDC0879 | Preclinical - Biochemical | Actionable | In a preclinical study, GDC-0879 inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | Sorafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | Belvarafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Belvarafenib (HM95573) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | Lifirafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Lifirafenib (BGB-283) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | Tovorafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Ojemda (tovorafenib) inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | TAK-632 | Preclinical - Biochemical | Actionable | In a preclinical study, TAK-632 inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - resistant | Dabrafenib | Preclinical - Biochemical | Actionable | In a preclinical study, Tafinlar (dabrafenib) did not inhibit Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |
BRAF L485_P490delinsFS | Advanced Solid Tumor | predicted - sensitive | LXH 254 | Preclinical - Biochemical | Actionable | In a preclinical study, LXH 254 inhibited Mek and Erk phosphorylation in cells expressing BRAF L485_P490delinsFS in culture (PMID: 37656784). | 37656784 |